Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: A systematic review

Lauren K. Dillard; Ricardo X. Martinez; Lucero Lopez Perez; Amanda M. Fullerton; Shelly Chadha; Catherine M. McMahon

doi:10.1016/j.jinf.2021.05.010

Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: A systematic review

Lauren K. Dillard^*, Ricardo X. Martinez, Lucero Lopez Perez, Amanda M. Fullerton, Shelly Chadha, Catherine M. McMahon

^*Corresponding author for this work

Department of Linguistics

Research output: Contribution to journal › Review article › peer-review

38 Citations (Scopus)

141 Downloads (Pure)

Abstract

Objectives estimate the prevalence of ototoxic hearing loss in drug-resistant tuberculosis (DR-TB) patients treated with aminoglycoside antibiotics via a systematic review and meta-analysis. Estimate the annual preventable cases of hearing loss in DR-TB patients and leverage findings to discuss primary, secondary and tertiary prevention.

Methods studies published between 2005 and 2018 that reported prevalence of post-treatment hearing loss in DR-TB patients were included. We performed a random effects meta-analysis to determine pooled prevalence of ototoxic hearing loss overall and by medication type. Preventable hearing loss cases were estimated using World Health Organization (WHO) data on DR-TB treatment and prevalence determined by the meta-analysis.

Results eighteen studies from 10 countries were included. Pooled prevalence of ototoxic hearing loss and the corresponding 95% confidence interval (CI) was 40.62% CI [32.77– 66.61%] for all drugs (kanamycin: 49.65% CI [32.77– 66.61%], amikacin: 38.93% CI [26.44–53.07%], capreomycin: 10.21% CI [4.33–22.21%]). Non-use of aminoglycosides may result in prevention of approximately 50,000 hearing loss cases annually.

Conclusions aminoglycoside use results in high prevalence of ototoxic hearing loss. Widespread prevention of hearing loss can be achieved by following updated WHO guidelines for DR-TB treatment. When hearing loss cannot be avoided, secondary and tertiary prevention should be prioritized.

Original language	English
Pages (from-to)	27-36
Number of pages	10
Journal	Journal of Infection
Volume	83
Issue number	1
DOIs	https://doi.org/10.1016/j.jinf.2021.05.010
Publication status	Published - 1 Jul 2021

Bibliographical note

Copyright © 2021 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Access to Document

10.1016/j.jinf.2021.05.010Licence: CC BY-NC-ND

Publisher version (open access)Final published version, 804 KBLicence: CC BY-NC-ND

Cite this

@article{e01573b8439e4534aaa1eec321925afa,

title = "Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: A systematic review",

abstract = "Objectives estimate the prevalence of ototoxic hearing loss in drug-resistant tuberculosis (DR-TB) patients treated with aminoglycoside antibiotics via a systematic review and meta-analysis. Estimate the annual preventable cases of hearing loss in DR-TB patients and leverage findings to discuss primary, secondary and tertiary prevention.Methods studies published between 2005 and 2018 that reported prevalence of post-treatment hearing loss in DR-TB patients were included. We performed a random effects meta-analysis to determine pooled prevalence of ototoxic hearing loss overall and by medication type. Preventable hearing loss cases were estimated using World Health Organization (WHO) data on DR-TB treatment and prevalence determined by the meta-analysis.Results eighteen studies from 10 countries were included. Pooled prevalence of ototoxic hearing loss and the corresponding 95% confidence interval (CI) was 40.62% CI [32.77– 66.61%] for all drugs (kanamycin: 49.65% CI [32.77– 66.61%], amikacin: 38.93% CI [26.44–53.07%], capreomycin: 10.21% CI [4.33–22.21%]). Non-use of aminoglycosides may result in prevention of approximately 50,000 hearing loss cases annually.Conclusions aminoglycoside use results in high prevalence of ototoxic hearing loss. Widespread prevention of hearing loss can be achieved by following updated WHO guidelines for DR-TB treatment. When hearing loss cannot be avoided, secondary and tertiary prevention should be prioritized.",

author = "Dillard, {Lauren K.} and Martinez, {Ricardo X.} and Perez, {Lucero Lopez} and Fullerton, {Amanda M.} and Shelly Chadha and McMahon, {Catherine M.}",

note = "Copyright {\textcopyright} 2021 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2021",

month = jul,

day = "1",

doi = "10.1016/j.jinf.2021.05.010",

language = "English",

volume = "83",

pages = "27--36",

journal = "Journal of Infection",

issn = "0163-4453",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients

T2 - A systematic review

AU - Dillard, Lauren K.

AU - Martinez, Ricardo X.

AU - Perez, Lucero Lopez

AU - Fullerton, Amanda M.

AU - Chadha, Shelly

AU - McMahon, Catherine M.

N1 - Copyright © 2021 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2021/7/1

Y1 - 2021/7/1

N2 - Objectives estimate the prevalence of ototoxic hearing loss in drug-resistant tuberculosis (DR-TB) patients treated with aminoglycoside antibiotics via a systematic review and meta-analysis. Estimate the annual preventable cases of hearing loss in DR-TB patients and leverage findings to discuss primary, secondary and tertiary prevention.Methods studies published between 2005 and 2018 that reported prevalence of post-treatment hearing loss in DR-TB patients were included. We performed a random effects meta-analysis to determine pooled prevalence of ototoxic hearing loss overall and by medication type. Preventable hearing loss cases were estimated using World Health Organization (WHO) data on DR-TB treatment and prevalence determined by the meta-analysis.Results eighteen studies from 10 countries were included. Pooled prevalence of ototoxic hearing loss and the corresponding 95% confidence interval (CI) was 40.62% CI [32.77– 66.61%] for all drugs (kanamycin: 49.65% CI [32.77– 66.61%], amikacin: 38.93% CI [26.44–53.07%], capreomycin: 10.21% CI [4.33–22.21%]). Non-use of aminoglycosides may result in prevention of approximately 50,000 hearing loss cases annually.Conclusions aminoglycoside use results in high prevalence of ototoxic hearing loss. Widespread prevention of hearing loss can be achieved by following updated WHO guidelines for DR-TB treatment. When hearing loss cannot be avoided, secondary and tertiary prevention should be prioritized.

AB - Objectives estimate the prevalence of ototoxic hearing loss in drug-resistant tuberculosis (DR-TB) patients treated with aminoglycoside antibiotics via a systematic review and meta-analysis. Estimate the annual preventable cases of hearing loss in DR-TB patients and leverage findings to discuss primary, secondary and tertiary prevention.Methods studies published between 2005 and 2018 that reported prevalence of post-treatment hearing loss in DR-TB patients were included. We performed a random effects meta-analysis to determine pooled prevalence of ototoxic hearing loss overall and by medication type. Preventable hearing loss cases were estimated using World Health Organization (WHO) data on DR-TB treatment and prevalence determined by the meta-analysis.Results eighteen studies from 10 countries were included. Pooled prevalence of ototoxic hearing loss and the corresponding 95% confidence interval (CI) was 40.62% CI [32.77– 66.61%] for all drugs (kanamycin: 49.65% CI [32.77– 66.61%], amikacin: 38.93% CI [26.44–53.07%], capreomycin: 10.21% CI [4.33–22.21%]). Non-use of aminoglycosides may result in prevention of approximately 50,000 hearing loss cases annually.Conclusions aminoglycoside use results in high prevalence of ototoxic hearing loss. Widespread prevention of hearing loss can be achieved by following updated WHO guidelines for DR-TB treatment. When hearing loss cannot be avoided, secondary and tertiary prevention should be prioritized.

UR - http://www.scopus.com/inward/record.url?scp=85107450143&partnerID=8YFLogxK

U2 - 10.1016/j.jinf.2021.05.010

DO - 10.1016/j.jinf.2021.05.010

M3 - Review article

C2 - 34015383

AN - SCOPUS:85107450143

SN - 0163-4453

VL - 83

SP - 27

EP - 36

JO - Journal of Infection

JF - Journal of Infection

IS - 1

ER -

Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: A systematic review

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this